Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.
about
Amyloidosis in Retinal Neurodegenerative DiseasesAmyloid-β Receptors: The Good, the Bad, and the Prion ProteinPET Imaging of Epigenetic Influences on Alzheimer's DiseaseNeprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chancesSpotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to dateDiabetes mellitus and cognitive impairmentsInfluence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's Disease.Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer's Disease Model Mice Targeting Beta-Amyloid Production.Andrographolide Activates Keap1/Nrf2/ARE/HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by Aβ42 through Nrf2-Related Inflammatory Response.β-Amyloid peptides and amyloid plaques in Alzheimer's disease.Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.Study of Exosomes Shed New Light on Physiology of Amyloidogenesis.New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.Sex Hormone Decline and Amyloid β Synthesis, Transport and Clearance in the Brain.Hypoxia Affects Neprilysin Expression Through Caspase Activation and an APP Intracellular Domain-dependent Mechanism.The Degradome database: expanding roles of mammalian proteases in life and disease.Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues.The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta.Editorial on, "Amyloid-beta clearance in Alzheimer's disease".Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.Neuroinflammatory responses in Alzheimer's disease.Alzheimer's disease and modern lifestyle: what is the role of stress?Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?
P2860
Q26739839-E847C5A4-0A42-4EDA-87F3-994E417D7BF3Q26771532-9B262321-EEE4-40F9-B0DF-77D6607CE153Q26776178-A534DC72-8A88-4689-A8FE-63D9AA31EB58Q27027707-D2872C07-EC36-4E47-9AF8-07BE835135B1Q28070064-A74CC54F-DE8E-4933-B016-68B0FCF0FC8CQ28079459-6629BFBA-2F9F-4A48-9B3C-1DAA577042B5Q36036376-C07A612F-C3B7-477B-8905-AB2DD3FF39D8Q37595978-47053E85-3375-4742-95AE-752A71776C43Q37685356-7237F554-9DA4-4B5F-B5E4-F2B988C99744Q37714716-D0F490CC-8884-492C-BA15-BA9EB5B020B7Q38265124-DB07D725-8857-4ACC-8ECC-4106BC7AA822Q38685645-82EDDDF9-A250-44F0-A45A-5B2269D36AFFQ38777380-2991E0E9-54C7-49B4-9E7B-711BE7CF1D9EQ38834930-4A1395AA-3730-4C35-9118-2B41124F40D0Q38955319-11B89C77-470D-4DF7-B62F-C852AAF28C07Q40263247-498C0DAB-B850-41BE-9E75-7D5C50CB35F2Q40338688-292C218C-FCFF-4EC2-AA67-D362BDA1C3B0Q41190059-74639BB2-13A3-43BC-84A3-135002723E4AQ41549636-4C4439E4-D72E-4E34-81B7-6CE889F6CA78Q42621653-E4E7355F-C720-426D-A578-03D0F93006DCQ43015317-6D8E07C2-DB55-4F4D-94CE-4D26CD8463AAQ47195553-3FC50989-D760-4FAC-8646-1115A645D621Q47259208-1300C222-1A16-42AE-9628-B53C03C22201Q53366494-6904252B-A283-41C2-8290-F26E8B1115BCQ58804503-C4BCF594-366F-4117-B90F-C79B15103CE1
P2860
Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Amyloid-clearing proteins and ...... target in Alzheimer's disease.
@en
type
label
Amyloid-clearing proteins and ...... target in Alzheimer's disease.
@en
prefLabel
Amyloid-clearing proteins and ...... target in Alzheimer's disease.
@en
P2093
P2860
P356
P1476
Amyloid-clearing proteins and ...... target in Alzheimer's disease.
@en
P2093
Anthony J Turner
Caroline Kerridge
Natalia N Nalivaeva
Nikolai D Belyaev
P2860
P356
10.3389/FNAGI.2014.00235
P577
2014-09-17T00:00:00Z